New York, NYNCT06656494Now EnrollingIRB Ready

Acute Myelogenous Leukemia Clinical Trial in New York, NY

Access cutting-edge acute myelogenous leukemia treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access acute myelogenous leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute myelogenous leukemia treatment provided free

Apply for This New York Location

Check if you qualify for this acute myelogenous leukemia clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Acute Myelogenous Leukemia Study in New York

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Who Can Participate

Inclusion Criteria

Eligible subjects must meet all of the following criteria:
Subject must have confirmation of diagnosis of AML (except for acute promyelocytic leukemia \[APL\]) or MDS per 2016 World Health Organization (WHO) criteria.
For AML (except for APL) cohort:
Previously treated relapsed/refractory AML subjects
Treatment-naïve AML subjects should be: ≥60 years of age OR ≥18 years and \<60 years will be eligible if the subject has at least one of the following co-morbidities, which make the subject unfit for intensive chemotherapy
For MDS cohort: Adult TN MDS and R/R MDS: revised International Prognostic Scoring System (IPSS-R) score \> 3 and bone marrow blasts ≥ 5%.
Subject must have a projected life expectancy of at least 12 weeks.
Subject must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft-Gault formula.
Subject must have adequate liver function

Exclusion Criteria

R/R AML or R/R MDS with no response or intolerance to post azacitidine or BCL-2i.
Subject has acute promyelocytic leukemia (French-American-British Class M3 AML) .
Subject has known central nervous system (CNS) leukemia.
Suggest patients with active hepatitis B or C virus infection
History of immunodeficiency, including a positive human immunodeficiency virus (HIV) antibody test.
Subjects have another active malignancy within the past 2 years before study entry, except for curatively treated.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT06656494) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Myelogenous Leukemia Treatment Options in New York, NY

If you're searching for acute myelogenous leukemia treatment options in New York, NY, this clinical trial (NCT06656494) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myelogenous leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute myelogenous leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in New York, NY

See all leukemia clinical trials recruiting in New York — not just this study.

Browse Leukemia Trials in New York →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsHeart Attack TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY